Response to Sanofi's form letter:
Is Sanofi interested in diabetes or just selling insulin?--Beta Recovery is not Islet Recovery
Please be informed that Beta Recovery is not Islet Recovery. If Sanofi doesn't know the difference between an islet and beta cell, I'm not comfortable using your insulin. Beta Cell Recovery is not associated with a cure for diabetes, whereas, Islet Neogenesis is. Does Sanofi-Aventis expect to be taken seriously as a diabetes company? I'm not a scientist, but I know the difference between beta cells and islets. Does Sanofi-Aventis know this?
At the very least, as person with diabetes, please tell your company that beta recovery is not the same as islet neogenesis. As the article explains, beta cells are not islets and islets are not beta cells. Please share this simple paragraph with Dr. Maas and Mr. Viehbacher. Mayber it will mean more coming from you as an employee of Sanofi. Thank you. Patrice.
From the Journal of Diabetes 2(2010) 76–84
The terms islet and beta cell are often used interchangeably, yet islets are highly complex multicellular organelles that contain the insulin-producing beta cell and four other cells types, all of which, play a role in maintaining glucose homeostasis within a very narrow range. While the formation of new islets in adults is rare, occurring primarily in response to pancreatic injury and major stress to the pancreas, beta cell replication from existing cells occurs throughout adulthood. Understanding of regulatory factors controlling pancreatic development has more clearly defined the differences between new islet formation from progenitor cells located throughout the adult pancreas and beta cell replication occurring within existing islets. This review sets forth to more clearly distinguish the differences between the postnatal pathways of islet neogenesis and beta cell replication with a discussion of the potential implications for reversal of type 1 and 2 patients utilizing islet neogenesis agents that are now in development. For type 1 patients, an immune tolerance agent in conjunction with an islet neogenesis agent may allow achievement of adequate islet mass, perhaps with subsequent potential to withdraw medications. For type 2 patients, lifestyle changes and/or medications may sustain production of new islets and limit the accelerated beta cell apoptosis characteristic of the condition.